Antibodies market
Antibodies Market, By Drug Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs), by Disease Indication (CNS Disorders, Cardiovascular, Cancer, Autoimmune Disorders, COVID-19, Others) By End User (Hospitals, Long-term Care Facilities, Research institutes), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
- Apr 2023
- CMI2629
- 170 Pages
- Excel & Pdf
- Biotechnology
The global antibodies market is estimated to be valued at US$ 224,083.5 million in 2023 and is expected to exhibit a CAGR of 12.9% during the forecast period (2023-2030).
Analysts’ Views on Global Antibodies Market:
Increasing inorganic strategies such as collaborations by the key market players is expected to drive the global antibodies market over the forecast period. For instance, in March 2022, Sanofi, a pharmaceutical and healthcare company, and Seagen Inc., a biotechnology company, announced a collaboration agreement, to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology
Figure 1. Global Antibodies Market Share (%), By Drug Type, 2023
Global Antibodies Market – Driver
Increase in inorganic strategies
Increasing inorganic strategies such as collaboration by the key market players is expected to drive the global antibodies market over the forecast period. For instance, in September 2020, Eli Lilly and Company, a pharmaceutical company and Amgen, an U.S. based multinational biopharmaceutical company, announced a global antibody manufacturing collaboration, to significantly increase the supply capacity available for Lilly's potential COVID-19 therapies.
Figure 2. Global Antibodies Market Value (US$ Million), By Region, 2023
Global Antibodies Market- Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global antibodies market over the forecast period.
Global Antibodies Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.
The COVID-19 affected the antibodies market positively as demand for the antibodies increased. For instance, in January 2022, a data was published by the Biomed Central, an open access publisher, according to that, The development and approval of vaccines and nAbs against COVID-19 have happened incredibly quickly due to collaborative efforts among the global scientific community. The U.S. government has placed a pre-order for 100 million doses of Pfizer's BNT162b2 mRNA vaccine at a cost of $1.95 billion as early as July 22, 2020, and after one year, it has already placed orders for a total of 500 million doses.
Global Antibodies Market Segmentation:
The global antibodies market report is segmented into Drug Type, Disease Indication, End User, and Region
Based on Drug Type, the market is segmented into monoclonal antibodies, polyclonal antibodies, and antibody-drug complexes (ADCs). Out which the monoclonal antibodies segment is expected to hold a dominant position in the antibodies market over the forecast period.
Based Disease Indication, the antibodies market is segmented into CNS disorders, cardiovascular diseases, cancer, and autoimmune disorders.
Based on End User, the antibodies market is segmented into hospitals, long-term care facilities, and research institutes.
Antibodies Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 224,083.5 Mn |
Historical Data for: | 2017 to 2021 | Forecast Period: | 2023 to 2030 |
Forecast Period 2023 to 2030 CAGR: | 12.9% | 2030 Value Projection: | US$ 524,782.9 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Kyowa Kirin Co., Ltd. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Global Antibodies Market Cross Sectional Analysis:
In drug type, the monoclonal antibodies segment is expected to hold a dominant position in the global antibodies market in North America over the forecast period. For instance, in October 2020, the U.S. Department of Health and Human Services (HHS), and Department of Defense (DOD), announced an agreement with AstraZeneca for late-stage development and large-scale manufacturing of the company’s COVID-19 investigational product AZD7442, a cocktail of two monoclonal antibodies, for the treatment against the SARS-CoV-2, the coronavirus that causes COVID-19.
Global Antibodies Market: Key Developments
For instance, in October 2020, IAVI, a nonprofit scientific research organization, and Serum Institute of India Pvt. Ltd., a manufacturer of vaccines and biologics, announced an agreement with Merck KGaA, a science and technology company, to develop SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research as innovative interventions to address the COVID-19 pandemic.
Global Antibodies Market: Key Trends
Increasing authorizations for antibodies by the regulatory authorities
Increasing authorizations by the regulatory authorities is expected to drive the global antibodies market over the forecast period. For instance, in May 2021, Roche India, announced that the Central Drugs Standards Control Organization (CDSCO) has provided an Emergency Use Authorization (EUA) for Roche’s antibody cocktail (Casirivimab and Imdevimab) in India.
Global Antibodies Market: Restraint
Side effects associated with the antibodies
Use of antibodies may lead to some side effects such as serum sickness, acute anaphylaxis, and specific target-related adverse effects, which is also expected to hinder the market growth. To overcome the adverse effects of the drugs and antibodies, regulatory authorities should strictly monitor the products.
Global Antibodies Market - Key Players
Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Lilly., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd.
*Definition: An antibody, also called immunoglobulin, is a protein produced by plasma cells in response to specific antigens. These antibodies can be used as therapeutic as well as diagnostic purposes for several indications, including cancers, autoimmune disorders, inflammatory & infectious diseases, and others.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- Product Launch
- Technological Advancements
- PEST Analysis
- Regulatory Scenario
- Mergers and Acquisitions
- Market Dynamics
- Global Antibodies Market- Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
- Global Antibodies Market, By Drug Type, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Polyclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Antibody-drug complexes (ADCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Introduction
- Global Antibodies Market, By Disease Indication, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- CNS Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- COVID-19
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$
- Introduction
- Global Antibodies Market, By End User, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segments Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Long-term Care Facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Research institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Introduction
- Global Antibodies Market, By Region, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Novartis International AG*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Iovance Biotherapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ultragenyx Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Kyowa Kirin Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis International AG*
- Section
- Research Methodology
- About Us
*Browse 36 market data tables and 27 figures on “Global Antibodies Market” - Global forecast to 2030
Detailed Segmentation:
- Global Antibodies Market, By Drug Type:
-
- Monoclonal antibodies
- Polyclonal antibodies
- Antibody-drug complexes (ADCs)
- Global Antibodies Market, By Disease Indication:
-
- CNS Disorders
- Cardiovascular Diseases
- Cancer
- Autoimmune Disorders
- COVID-19
- Others
- Global Antibodies Market, By End User:
- Hospitals
- Long-term Care Facilities
- Research institutes
- Global Antibodies Market, By Region:
- North America
- By Drug Type:
- Monoclonal antibodies
- Polyclonal antibodies
- Antibody-drug complexes (ADCs)
- By Disease Indication:
- CNS Disorders
- Cardiovascular Diseases
- Cancer
- Autoimmune Disorders
- COVID-19
- Others
- By End User:
- Hospitals
- Long-term Care Facilities
- Research institutes
- By Country:
- U.S.
- Canada
- By Drug Type:
- Latin America
- By Drug Type:
- Monoclonal antibodies
- Polyclonal antibodies
- Antibody-drug complexes (ADCs)
- By Disease Indication:
- CNS Disorders
- Cardiovascular Diseases
- Cancer
- Autoimmune Disorders
- COVID-19
- Others
- By End User:
- Hospitals
- Long-term Care Facilities
- Research institutes
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Type:
- Europe
- By Drug Type:
- Monoclonal antibodies
- Polyclonal antibodies
- Antibody-drug complexes (ADCs)
- By Disease Indication:
- CNS Disorders
- Cardiovascular Diseases
- Cancer
- Autoimmune Disorders
- COVID-19
- Others
- By End User:
- Hospitals
- Long-term Care Facilities
- Research institutes
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Drug Type:
- Asia Pacific
- By Drug Type:
- Monoclonal antibodies
- Polyclonal antibodies
- Antibody-drug complexes (ADCs)
- By Disease Indication:
- CNS Disorders
- Cardiovascular Diseases
- Cancer
- Autoimmune Disorders
- COVID-19
- Others
- By End User:
- Hospitals
- Long-term Care Facilities
- Research institutes
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Drug Type:
- Middle East
- By Drug Type:
- Monoclonal antibodies
- Polyclonal antibodies
- Antibody-drug complexes (ADCs)
- By Disease Indication:
- CNS Disorders
- Cardiovascular Diseases
- Cancer
- Autoimmune Disorders
- COVID-19
- Others
- By End User:
- Hospitals
- Long-term Care Facilities
- Research institutes
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug Type:
- Africa
- By Drug Type:
- Monoclonal anti bodies
- Polyclonal antibodies
- Antibody-drug complexes (ADCs)
- By Disease Indication:
- CNS Disorders
- Cardiovascular Diseases
- Cancer
- Autoimmune Disorders
- COVID-19
- Others
- By End User:
- Hospitals
- Long-term Care Facilities
- Research institutes
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Drug Type:
- North America